Kyverna Therapeutics
anti-CD19 CAR-T cell therapy for autoimmune diseases
- Sector
- Biotech
- Headquarters
- EMERYVILLE, CA
- Latest Form D
- $152M, Nov 2023
- Total capital
- $152M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $152M
- 1 Form D · last Nov 2023
- 36 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 38 pending · first 2022
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$152M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Beth SpiegelmanDirectorNamed in SEC Form D filings
- Brian KotzinDirectorNamed in SEC Form D filings
- Dan SpiegelmanDirectorNamed in SEC Form D filings
- Dominic BorieExecutive OfficerNamed in SEC Form D filings
- Fred CohenDirectorNamed in SEC Form D filings
- Ian ClarkDirectorNamed in SEC Form D filings
Show all 11 people
- James ChungExecutive OfficerNamed in SEC Form D filings
- Karen WalkerExecutive OfficerNamed in SEC Form D filings
- Peter MaagExecutive Officer, DirectorNamed in SEC Form D filings
- Ryan JonesExecutive OfficerNamed in SEC Form D filings
- Steve LiapisDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 40- PendingMethods For Treating Autoimmune DiseasesUSPTOApplication 19402188
- PendingMethods For Treating Stiff Person Syndrome And Myasthenia Gravis Using ANTI-CD19 Car-t Cell TherapeuticsUSPTOApplication 18827646
- PendingMethods Of Treating Lupus Nephritis Using ANTI-CD19 Car-t Cell TherapiesUSPTOApplication 18827623
Show all 40 patent records
- Methods For Treating Autoimmune DiseasesMay 21, 2026 · Application 19402188Pending
- Methods For Treating Stiff Person Syndrome And Myasthenia Gravis Using ANTI-CD19 Car-t Cell TherapeuticsJan 30, 2025 · Application 18827646Pending
- Methods Of Treating Lupus Nephritis Using ANTI-CD19 Car-t Cell TherapiesDec 26, 2024 · Application 18827623Pending
- Methods And Compositions For Treating Autoimmune DiseaseAug 8, 2024 · Application 18329959Pending
- Methods For Increasing T-cell FunctionMay 16, 2024 · Application 18417170Pending
- Methods For Increasing T-cell FunctionJan 23, 2024 · US 11,879,003Granted
- Methods And Compositions For Treating Autoimmune DiseaseDec 14, 2023 · Application 18300919Pending
- Methods Of Producing T Regulatory Cells, Methods Of Transducing T Cells, And Uses Of The SameOct 19, 2023 · Application 17985587Pending
- Methods For Treating Autoimmune DiseasesJul 6, 2023 · Application 17984814Pending
- A Method For Treating Disease Using FOXP3+CD4+ T CellsApr 6, 2023 · Application 17979437Pending
- Methods And Compositions For Treating Disease Using Targeted FOXP3+CD4+ T Cells And Cellular Suicide AgentsFeb 23, 2023 · Application 17721927Pending
- A Method For Treating Disease Using FOXP3+CD4+ T CellsSep 20, 2022 · US 11,446,357Granted
- Method For Treating Disease Using FOXP3+CD4+ T CellsJun 2, 2022 · Application 17523431Pending
- Method For Treating Disease Using FOXP3+CD4+ T CellsApr 14, 2022 · Application 17499157Pending
- Methods Of Producing T Regulatory Cells, Methods Of Transducing T Cells, And Uses Of The SameFeb 3, 2022 · Application 17391767Pending
- Methods For Treating Myasthenia Gravis Using ANTI-CD19 Car-t Cell TherapiesApplication 63620673Pending
- Allogeneic Car-t Cell Therapies And Manufacture ThereofApplication 63620643Pending
- Methods For Treating Systemic Sclerosis Using ANTI-CD19 Car-t Cell TherapiesApplication 63597233Pending
- Methods For Treating Myasthenia Gravis Using ANTI-CD19 Car-t Cell TherapiesApplication 63596770Pending
- Methods For Treating Myasthenia Gravis Using ANTI-CD19 Car-t Cell TherapiesApplication 63596951Pending
- Methods For Manufacture Of Engineered T Cells From Whole Blood SamplesApplication 63547255Pending
- Methods For Treating Multiple Sclerosis Using ANTI-CD19 Car-t Cell TherapiesApplication 63594837Pending
- Methods For Treating Lupus Nephritis Using ANTI-CD19 Car-t Cell TherapiesApplication PCTUS2023077760Pending
- Methods For Treating Systemic Sclerosis Using ANTI-CD19 Car-t Cell TherapiesApplication 63589588Pending
- Methods For Treating Systemic Sclerosis Using ANTI-CD19 Car-t Cell TherapiesApplication 63587991Pending
- Methods For Treating Lupus Nephritis Using ANTI-CD19 Car-t Cell TherapiesApplication 63587329Pending
- Allogeneic Car-t Cell Therapies And Manufacture ThereofApplication 63579076Pending
- Methods For Treating Lupus Nephritis Using ANTI-CD19 Car-t Cell TherapiesApplication 63518745Pending
- Methods For Rapid Manufacture Of Engineered T Cells Expressing Chimeric Antigen ReceptorsApplication 63518503Pending
- Methods For Treating Myasthenia Gravis Using ANTI-CD19 Car-t Cell TherapiesApplication 63516378Pending
- Methods For Rapid Manufacture Of Engineered T Cells Expressing Chimeric Antigen ReceptorsApplication 63515025Pending
- Methods Of Treating Lupus Nephritis Using ANTI-CD19 Car-t Cell TherapiesApplication 63512061Pending
- Methods And Compositions For Treating Autoimmune DiseaseApplication PCTUS2023067972Pending
- Methods And Compositions For Treating Autoimmune DiseaseApplication PCTUS2023065782Pending
- Methods For Treating Autoimmune DiseasesApplication PCTUS2023010034Pending
- Methods For Treating Autoimmune DiseasesApplication 63419193Pending
- Methods And Compositions For Treating Autoimmune DiseaseApplication 63350141Pending
- Methods And Compositions For Treating Disease Using Targeted FOXP3+CD4+ T Cells And Cellular Suicide AgentsApplication PCTUS2022025033Pending
- Methods And Compositions For Treating Autoimmune DiseaseApplication 63331397Pending
- Methods Of Producing Regulatory T Cells And Use Of The SameApplication PCTUS2022018324Pending
Related companies, and why
- Treeline BiosciencesSimilar federal contract value in Biotech · null in contracts
- ESTRIGENIX THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Cognito Therapeutics Ltd.Similar federal contract value in Biotech · null in contracts
- Gilgamesh PharmaSimilar federal contract value in Biotech · null in contracts
- Liminal BioSciences Inc.Similar federal contract value in Biotech · null in contracts
- Ernexa Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .